Valbenazine adverse effects with 2.7-5.4% frequency?

Valbenazine adverse effects with 2.7-5.4% frequency?

• A. Anticholinergic adverse effects
• B. Arthralgia
• C. Nausea
• D. Dizziness

Answer: (A)

Valbenazine is a VMAT2 inhibitor used for tardive dyskinesia, and its adverse effect profile includes anticholinergic symptoms that occur at a relatively low frequency—about 3% to 5% of patients. These anticholinergic effects can include dry mouth, constipation, blurred vision, or urinary retention. They are less common than some other adverse effects like somnolence or fatigue, which is why the 2.7–5.4% range is noted specifically for this channel of adverse effects. The other options—arthralgia, nausea, and dizziness—occur with different frequencies and are not the adverse effects classically labeled as anticholinergic in this medication.

Valbenazine is a VMAT2 inhibitor used for tardive dyskinesia, and its adverse effect profile includes anticholinergic symptoms that occur at a relatively low frequency—about 3% to 5% of patients. These anticholinergic effects can include dry mouth, constipation, blurred vision, or urinary retention. They are less common than some other adverse effects like somnolence or fatigue, which is why the 2.7–5.4% range is noted specifically for this channel of adverse effects. The other options—arthralgia, nausea, and dizziness—occur with different frequencies and are not the adverse effects classically labeled as anticholinergic in this medication.